Why the study?
Limited information is available regarding the quality of lifelong VKA therapy, AF, and their relationship with adverse events after mechanical AVR.
Does suboptimal time in therapeutic range (TTR < 80%) during VKA therapy increase the risk of adverse events and mortality in patients with mechanical AVR and AF?
Cohort (n=1,086)
Yes
Does suboptimal time in therapeutic range (TTR < 80%) during VKA therapy increase the risk of adverse events and mortality in patients with mechanical AVR and AF?
In patients with mechanical AVR and AF, suboptimal TTR (<80%) during VKA therapy is associated with significantly higher risks of bleeding, ischemic stroke, and mortality.
Answers are grounded in this paper and cite their sources.
Supports closer INR monitoring in mechanical AVR with AF; leaves open whether TTR optimization reduces events in trials.
AIMS: Mechanical aortic valve replacement (AVR) remains the primary treatment for younger patients with severe aortic valve disease. However, limited information is available regarding the quality of the required lifelong vitamin K antagonist (VKA) therapy, atrial fibrillation (AF), and their relationship with adverse events after AVR. This study assessed the quality of VKA therapy prior to bleeding and ischaemic events following mechanical AVR in patients with AF. METHODS AND RESULTS: The registry-based Finnish AntiCoagulation in Atrial Fibrillation study combining data from several Finnish healthcare registers covers all patients diagnosed with AF during 2007-18 in Finland. This analysis included patients undergoing mechanical AVR before or after the AF diagnosis. A total of 1086 patients with mechanical AVR and AF either before (41.2%) or after (58.8%) the operation were identified. Cumulative incidence estimates at 10 years after AVR were 27.9% for significant bleeding, 5.8% for intracranial haemorrhage, 12.8% for ischaemic stroke, and 7.2% for myocardial infarction. Time in therapeutic range (TTR) < 80% with international normalized ratio (INR) target 2.0-3.5 was associated with higher bleeding occurrence [adjusted hazard ratio (aHR) 1.97, 1.39-2.79, P < 0.001]. Time in therapeutic range with INR target ≥2.0 was associated with higher stroke occurrence (aHR/standard deviation 1.22, 1.01-1.46, P = 0.035). Mortality was high (28.9%/10 years), and TTR <80% was associated with higher mortality (aHR 2.74, 2.00-3.76, P < 0.001). CONCLUSION: Adverse events, particularly major bleeding, are common in patients with AF following mechanical AVR, and mortality is high. Suboptimal TTR appears to predict bleeding episodes, ischaemic stroke, and death, and it could be useful in high-risk patient identification and targeting of preventive strategies. TRIAL REGISTRATION: Finnish AntiCoagulation in Atrial Fibrillation study, ClinicalTrials Identifier: NCT04645537, https://clinicaltrials.gov/ct2/show/NCT04645537.
No takes yet. Share an insight, caveat, or question.
Lehto et al. (2025) conducted a cohort in Atrial fibrillation and mechanical aortic valve replacement (n=1,086). Suboptimal time in therapeutic range (TTR < 80%) vs. TTR ≥ 80% was evaluated on Bleeding occurrence (aHR 1.97, 95% CI 1.39-2.79, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: